Serotonergic

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Entheogens, Mycotoxins, Hallucinations, Serotonin, Psilocybin, Serotonergic

Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions.

Key Points: 
  • Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions.
  • The OTCQB has rigorous compliance and quality standards, thus providing investors improved visibility to enhance trading decisions.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.\n'

Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Neuroscience, Neurotransmitters, TAAR1 agonists, Psychedelic drugs, Hydroxyarenes, Serotonin, Serotonergic, Psilocybin

b'The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.\nBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.

Key Points: 
  • b'The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.\nBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.\n'

Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast live at the aforementioned time and available for one week thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for one week thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

Retrieved on: 
Friday, February 5, 2021
Branches of biology, Neuroscience, Neurotransmitters, Hallucinations, Psychedelic drugs, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic, Serotonergic psychedelic

Bright Minds is focused on modern-day drug design and aims to improve on first-generation psychedelics by creating drugs that are selective serotonin agonists.

Key Points: 
  • Bright Minds is focused on modern-day drug design and aims to improve on first-generation psychedelics by creating drugs that are selective serotonin agonists.
  • Today marks a significant milestone for Bright Minds, as we officially become a publicly traded company.
  • Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.